R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
Digital Why security-first design is the fix to stalling AI pilot to... For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach.
Digital From pilots to impact: What it really takes to scale GenAI i... Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of-concepts.
Digital Pharma's AI is missing the "Why” Artificial intelligence (AI) is reshaping the pharmaceutical industry, driving advances from drug discovery and clinical trial acceleration to manufacturing optimisation and commercialisati
Patients 2025 predictions and AI trends for pharma executives The role of technology – particularly artificial intelligence (AI) – is top of mind for pharma executives this year (if it isn’t already).
Digital Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long... In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face